ストックスクリーナーアプリを入手
14.18
5.34%
-0.80
Myriad Genetics Inc (MYGN) 最新ニュース
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay - MSN
Peregrine Capital Management LLC Boosts Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics Included in Forbes America’s Best Employers 2025 List - GlobeNewswire
This Healthcare Giant's Employee Satisfaction Rate Crushes Industry Average by 27% - StockTitan
Myriad Genetics (MYGN) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 - GlobeNewswire
Pancreatic Cancer Diagnostic Market to Reach $3.2 billion, Globally, by 2035 at 5.9% CAGR: Allied Market Research - GlobeNewswire Inc.
Myriad Genetics Sets Stage for Major Q4 Financial Reveal: 3 Key Investor Conferences Follow - StockTitan
Myriad Genetics (NASDAQ:MYGN) Trading 8.3% HigherHere's What Happened - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Earns Buy Rating from Analysts at Craig Hallum - MarketBeat
Myriad Genetics secures patents for cancer MRD tests - MSN
Insiders Sold US$6.5m Of Myriad Genetics Stock Possibly Sending Warning Sign - Simply Wall St
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Genomic Biomarker Market Projected To Witness Substantial Growth, 2025-2032: Myriad Genetics, Inc., Eurofins - EIN News
PARP Inhibitor Biomarkers Market Top Players- Myriad Genetics, - openPR
Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts - Benzinga
Craig-Hallum initiates Myriad Genetics stock with a Buy rating By Investing.com - Investing.com South Africa
MYGN Stock Might Rise on Collaboration With CancerCARE - MSN
Jennison Associates LLC Raises Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing - Nasdaq
Myriad Genetics and CancerCARE for Life Announce Agreement - GlobeNewswire
Major Healthcare Partnership: Myriad's Advanced Cancer Risk Test Now Available to Million-Plus Patients - StockTitan
Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay - GlobeNewswire
Predictive Genetic Counselling Market Size, Trends, - openPR
Myriad Genetics and Lumea Collaborate to Enhance Access to - GlobeNewswire
Myriad Genetics Get 2 Patents for Molecular Residual Disease Assay -February 05, 2025 at 05:41 pm EST - Marketscreener.com
Myriad Genetics secures patents for cancer MRD tests By Investing.com - Investing.com South Africa
Myriad Genetics Announces Two New Patents Granted For Its Molecular Residual Disease (MRD) Assay - Marketscreener.com
Myriad Genetics Partners With Lumea To Integrate Prolaris And MyRisk Tests Into BxLink Platform - Nasdaq
Myriad Genetics and Lumea Inc. Announce Integration of Advanced Molecular Diagnostic Tests into Digital Pathology Platform BxLink - Nasdaq
Lumea and Myriad Genetics Collaborate to Enhance Access to Biomarker and Hereditary Cancer Tests in BxLink - EIN News
Pancreatic Cancer Market Size USD 5.7 Billion, Opportunities, - openPR
Blue Trust Inc. Boosts Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - Defense World
Piper Sandler Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $14.00 - MarketBeat
Fifth Third Bancorp Sells 23,296 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Nisa Investment Advisors LLC - Defense World
Piper Sandler Issues Pessimistic Forecast for Myriad Genetics (NASDAQ:MYGN) Stock Price - Defense World
Myriad Genetics (NASDAQ:MYGN) Price Target Cut to $18.00 by Analysts at The Goldman Sachs Group - MarketBeat
Myriad Genetics Unveils Award-Winning Research on Early Prenatal Screening Technology at SMFM Conference - Nasdaq
Myriad Genetics Unveils Groundbreaking Eight Weeks’ - GlobeNewswire
Revolutionary Prenatal Test Gives Parents Answers 2 Weeks Earlier Than Ever Before - StockTitan
DNA Diagnostics Market Booming Demand: Growth Trends, Share, - openPR
0.06%
3.50%
大文字化:
|
ボリューム (24 時間):